Search
 

Trump nominee Azar faces another grilling on drug costs

President Donald Trumps pick to lead the U.S. Health and Human Services Department is likely to face questions on drug prices and Obamacare when he faces senators at his second hearing on Capitol Hill.

X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Alex Azar's role as an executive at drugmaker Eli Lilly & Co. has fueled lawmakers’ concerns that he might not be willing to take a tough stance against the pharmaceutical industry on drug prices. (Photo: HHS.gov)

High drug prices are sure to come up again. So is Obamacare.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

Recommended Stories

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.